Gene fusions and their chimeric products are common features of neoplasia. Given that many cancers arise by the dysregulated recapitulation of processes in normal development, we hypothesized that comparable chimeric gene products may exist in normal cells. Here, we show that a chimeric RNA, PAX3-FOXO1 , identical to that found in alveolar rhabdomyosarcoma, is transiently present in cells undergoing differentiation from pluripotent cells into skeletal muscle. Unlike cells of rhabdomyosarcoma, these cells do not seem to harbor the t(2;13) chromosomal translocation. Importantly, both PAX3-FOXO1 RNA and protein could be detected in the samples of normal fetal muscle. Overexpression of the chimera led to continuous expression of MYOD and MYOG-two myogenic markers that are overexpressed in rhabdomyosarcoma cells. Our results are consistent with a developmental role of a specifi c chimeric RNA generated in normal cells without the corresponding chromosomal rearrangement at the DNA level seen in neoplastic cells presumably of the same lineage.
INTRODUCTION
Gene fusions resulting from chromosomal rearrangements and most often interchromosomal translocations are considered a genetic hallmark of many neoplasias ( 1, 2 ) . Specifi c head-to-tail fusions of two genes are generally characteristic of individual subtypes of tumors and have become important diagnostic markers over the last several decades. As has been demonstrated by abundant experimental evidence, these chimeric products arising from these fusions are most often causally related to the neoplastic behavior of the cells and tumors containing them. Recently, we discovered in normal endometrial cells a form of chimeric mRNA and protein identical to that found in endometrial stromal sarcomas ( 3 ) . In normal endometrial stroma, this RNA seems to result from trans -splicing between precursor mRNAs transcribed from the two intact genes JAZF1 and JJAZ1 (also called SUZ12 ; ref. 3 ) . On the basis of these fi ndings, we hypothesized that at least some chimeric RNAs are present in certain normal cells of a tissue and play normal physiologic functions in those cells, and that gene fusions in neoplastic cells may produce the chimeras in a constitutive and unregulated fashion.
Because the chimeric proteins translated from these RNAs are oncogenic, we speculated that chimeric RNAs in normal cells appear only under certain conditions, for limited periods of time, and/or at low levels. In addition, such chimeric RNAs may be produced in the absence of chromosomal rearrangement in normal cells. Besides JAZF1-JJAZ1 , reports for other chimeric RNAs generated by non-chromosomal rearrangement mechanisms are also emerging. Recently, reciprocal RNA chimera involving YPEL5 and PPP1CB was identifi ed by transcriptome sequencing, and no corresponding rearrangement at the DNA level was found ( 4 ) . In addition, we reported cis -splicing of adjacent genes as another mechanism to generate SLC45A3-ELK4 chimera involving neighboring genes transcribing in the same direction ( 5 ) .
RESULTS
To test the hypothesis, we monitored normal bone marrowderived mesenchymal stem cells (MSC) induced to differentiate along the skeletal muscle lineage for expression of the chimeric RNA PAX3-FOXO1 , which is transcribed from a gene fusion found in over half the cases of alveolar rhabdomyosarcoma (ARMS), a soft-tissue sarcoma of children and young adults ( 6, 7 ) . Expression of PAX3-FOXO1 RNA could be detected transiently along the differentiation process, and the expression of PAX3-FOXO1 preceded the expression of myogenic early stage markers ( MYOD and MYOG ; Fig. 1A ) . Similar muscle differentiation studies were performed using another source of adult stem cells, adipose-derived stem cells (ASC) isolated from fat tissue removed by liposuction. In a representative study (total n = 3), PAX3-FOXO1 fusion RNA was detected at only one time point, day 8 ( Fig. 1B ) . As in the prior studies with bone marrow MSCs, the expression of PAX3-FOXO1 preceded the expression of MYOD and MYOG mRNA. Sequencing analysis revealed that the chimeric RNA detected during the differentiation was identical to the RESEARCH ARTICLE Figure 1 . Detection of PAX3-FOXO1 RNA during muscle differentiation and absence of chromosomal translocation in these cells. A representative of multiple repeats ( n > 3) is shown. Bone marrow MSCs (A) or ASCs (B) were induced to differentiate along a skeletal muscle lineage. RNA was extracted from samples harvested every other day from day 2 to day 18. PAX3-FOXO1 , MYOD , and MYOG RNAs were assessed by RT-PCR. RNA from the rhabdomyosar coma cell line RH30 was used as positive control. C, sequencing analysis of the above PAX3-FOXO1 reverse transcription PCR products revealed a nucleotide sequence at the PAX3-FOXO1 junction identical to the product generated from chromosomal translocation in alveolar rhabdomyosarcoma. D-F, FISH and cytogenetic analysis in bone marrow MSCs (D), ASCs (E), and RH30 (F). FISH was performed using a FOXO1 Dual Color BreakApart FISH probe Kit. Karyotyping analysis was done as described in Methods. 
RH30
PAX3-FOXO1 RNA found in ARMS (fi rst 7 exons of PAX3 joined to last 2 exons of FOXO1 ; Fig. 1C ) . Because of the stochastic nature of muscle differentiation in vitro , the exact time point of PAX3-FOXO1 expression varied in multiple repeating experiments, and sometimes another wave of expression was observed after the initial transient expression. However, PAX3-FOXO1 always preceded the expression of MYOD and MYOG ( Supplementary Fig. S1 ). In longer-term differentiation settings (28 days), Myosin heavy chain ( MYH ) transcript (Supplementary Fig. S1A and S1B) and MYH protein (Supplementary Fig. S2A ) were also detected, along with another feature of terminal skeletal muscle formation, multi-nucleation (Supplementary Fig. S2B ).
These adult stem cells from bone marrow and fat used in our studies were obtained from healthy non-cancer donors and contained normal numbers of chromosomes and G banding patterns in cytogenetic analyses ( Fig. 1D and E ) . In contrast, the ARMS cell line RH30 showed abnormal chromosomal banding and aneuploidy ( Fig. 1F ) . To further confi rm the absence in these normal cells of the t(2;13)(q35;q14) chromosomal translocation that produces the PAX3-FOXO1 fusion in ARMS, we used a clinically used diagnostic FISH kit for ARMS to detect recombination at the FOXO1 locus. A total of 200 cells from each of both stem cell cultures were scored. No separation of red and green signals was observed in the two types of stem cell cultures ( Fig. 1D and E ) , indicating the absence of a translocation involving FOXO1 . However, separation of multiple unpaired red and green fl uorescence signals was seen in RH30 cells ( Fig. 1F ) , consistent with the previous fi nding that this cell line has a complex karyotype with amplifi cation of the fusion gene ( 8 ) .
The timing of generation of PAX3-FOXO1 RNA did not correlate with that of wild-type PAX3 or FOXO1 RNA during the process, arguing against the possibility of nonspecifi c splicing due to high levels of wild-type transcripts. To further confi rm this fi nding, we developed quantitative PCR (qPCR) assays to measure the chimera and wild-type PAX3 (primers spanning intron 7) and FOXO1 (primers spanning intron 1) expression ( Supplementary Fig. S3 ). No correlation of the fusion expression level with either wild-type transcript was observed. In addition, no reciprocal FOXO1-PAX3 chimeric RNA was detected in the muscle differentiation samples, even though it is quite abundant in RH30.
We next investigated whether results obtained with cultured cells also occur in vivo during normal muscle development. We macrodissected muscle from sections of formalin-fi xed, paraffi n-embedded (FFPE) tissue from nine fetal abortuses that resulted from miscarriage or therapeutic abortion due to 
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placental previa or trisomy 18 or 21 (one case each). None of the fetuses from which the tissue was obtained showed abnormalities of chromosomes 2 or 13. Chimeric PAX3-FOXO1 RNA was detected in muscle tissues from two of these cases ( Fig. 2A ) . The PCR products were cloned and Sanger sequencing revealed identical sequence to that of PAX3-FOXO1 in RH30 cells.
Protein extracts were prepared from three fresh-frozen normal fetal abortuses. A band identical to PAX3-FOXO1 protein was detected using an antibody against FOXO1 by Western blot analysis in all three cases, but not in the negative control colon cancer cell line HCT116 ( Fig. 2B ). To further confi rm the identity of the band, we performed Western blot analysis on the same set of samples with a PAX3-FOXO1-specifi c monoclonal antibody (PFM2). The specifi city of the antibody has been demonstrated before ( 9 ) and further confi rmed (Supplementary Fig. S4 ). Using this antibody, we observed the same-size protein bands in two of these fetal samples ( Fig. 2B ) . The relative intensities of the bands corresponded to those in the FOXO1 antibody Western, even though the PFM2 blot has a much fainter signal. We then collected 17 fresh-frozen tissues from 14 fetuses ranging in gestation age from 10 to 18 weeks. Although some of the samples were heavily fragmented with no recognizable morphology, complicating the dissection of muscle tissues, PAX3-FOXO1 protein could be detected in most samples, with no obvious correlation with gestation stage ( Fig. 2C ). Similar to the observations with RNA in differentiating stem cell cultures, the detection of PAX3-FOXO1 protein mostly did not correlate with the level of wild-type full-length FOXO1 protein, which was below the level of detection in several of the samples positive for PAX3-FOXO1 protein.
To further confi rm the presence of the fusion transcript in the fetal samples, and to avoid potential artifacts caused by RT-PCR, we applied a NanoString nCounter technology, which uses unique color-coded molecular barcodes that hybridize directly to multiple target transcripts without reverse transcription and PCR amplifi cation ( 10 ) . In this system, each capture probe and reporter probe together query a contiguous 100 bp or so region. For fusion RNA targets, we designed the capture probe targeting primarily the sequence 5′ to the fusion junction site, and reporter probe targeting the other side. Together, the probes are specifi c for the fusion, as either of the two wild-type transcripts will not hybridize to at least one probe. Multiple evidence shown in Fig. 3A suggests that the probe set for PAX3-FOXO1 is specifi c: (i) A very strong signal was observed in HEK293 cells transfected with a PAX3-FOXO1 -expressing plasmid. In contrast, no signal above background was detected in cells transfected with a PAX3 -or FOXO1 -expressing plasmid; (ii) a fusion-specifi c siRNA ( 11 ) ; lanes 2-9, normal karyotype; lane 10, blank paraffi n. GAPDH RNA was set up as internal control for total RNA input and integrity. B, total cellular protein was extracted from samples of three frozen normal abortuses. Western blot analysis was performed using FOXO1 or PFM2 antibodies. Protein from the colon cancer cell line HCT116 was used as a negative control. GAPDH was used as a loading control. C, total protein was extracted from 17 fresh-frozen tissue samples of 14 fetuses. Western blot analysis was performed using a FOXO1 antibody. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. C   RH30  FS18  FS15  FS17  FS19  FS23  FS6  FS14  FS20  FS9-1  FS9-2  FS9-3  FS22   10  1 2 3 
included as negative controls. None of the samples tested had a signal above background for these two fusions.
Even though all the fetal samples were from non-cancer abortuses, it is still possible that a small percentage of cells harboring t(2;13) is responsible for the PAX3-FOXO1 signal. In the above NanoString nCounter assay, the signals of PAX3-FOXO1 in the two fetal samples (FS17 and FS40) are about 3% of that in RH30. To get a better estimate on the expression level of PAX3-FOXO1 (which refl ects the percentage of PAX3-FOXO1 -expressing cells) in the fetal samples, we used standards with RNA extracted from serial dilutions of RH30 cells in the prostate cancer cell PC3 (negative for PAX3-FOXO1 ) in TaqMan qRT-PCR ( Fig. 3B ) . Three continuous sections were cut at a 5-μm thickness for FS7 and FS18. The middle section was subject to RNA purifi cation and TaqMan qRT-PCR. Assuming that the fusion is expressed at a similar level in fusion-expressing cells in the fetal samples as in RH30 cells, we estimated that the percentage of PAX3-FOXO1 -expressing cells is about 1% in FS7 and 0.1% in FS18 ( Fig. 3B ) . These numbers may be underestimated, as RH30 cells have several copies of the fusion DNA ( Fig. 1F ) and they seem to be upregulated. We then performed the FISH analysis with FOXO1 break-apart probes on the top and bottom sections of each sample. At the 5-μm thickness, 18%-27% of Table S1 ), indicating that a higher percentage of cells were split onto two slides. We scanned multiple fi elds and scored more than 1,500 cells for each section (1,508 for FS7 top, 2,007 for FS7 bottom, 2,266 for FS18 top, and 1,550 for FS18 bottom). No evidence of FOXO1 breakage was found (examples in Fig. 3C and Supplementary S6), suggesting the mechanism for the fusion in these cells is unlikely to be chromosomal translocation ( P < 0.001 for FS7 and P < 0.05 for FS18).
The PAX3-FOXO1 fusion protein has greater transcriptional activity than wild-type PAX3 both in vitro and in vivo ( 12 ) . Studies in fi broblast and rhabdomyosarcoma cell lines have demonstrated that the PAX3-FOXO1 protein simultaneously induces myogenesis while blocking differentiation to mature muscle, thereby contributing to the formation of ARMS ( 13, 14 ) . To test the effect of constant expression of PAX3-FOXO1 in the muscle differentiation setting, MSC cells were infected with retroviral vectors that overexpress PAX3-FOXO1 ( Fig. 4A ) . Under the differentiation condition, MYOD and MYOG were continuously expressed from day 2 to day 24 in the cells overexpressing PAX3-FOXO1 ( Fig. 4B ), in contrast with the transient expression pattern seen in Fig. 1 . No mature muscle marker MYH expression was observed at any time point when the ectopic fusion was continuously expressed (data not shown), consistent with a role of PAX3-FOXO1 in suppressing terminal differentiation.
We then performed paired-end RNA sequencing (RNAseq) on MSC samples collected at four different time points [D4, D14, D22 (positive for PAX3-FOXO1 ) and D26], together with RH30. We then used deFuse software ( 15 ) to identify fusion RNAs and RT-PCR to validate them. Not surprisingly, the average number of fusions in these normal MSC samples ( n = 7) is much smaller than that in RH30 ( n = 29; Fig. 5 ; Table 1 and Supplementary Table S2 ). Out of the 30 fusions, 27 were detected only at one time point and three were detected at two time points, suggesting the transient nature of these fusions. Nothing is known about the three fusions, 7SK.206-STX3 , KDELR1-GRIN2D , and RP11-312O7.2-SRGAP2 . However, the fact they were found in MSC D26 as well as in MSC D4 or D14, but not in MSC D22, also supports the wave expression pattern we observed in Supplementary Fig. S1 . The majority of the 30 fusions are intrachromosomal, as only three interchromosomal fusions were detected in all the 30 fusions found in MSC samples, including PAX3-FOXO1 . Consistent with other results presented above, PAX3-FOXO1 was only transiently detected in MSC D22, and only two other fusions were found in the same sample. None of these two fusions was detected in RH30 cells, further confi rming the uniqueness of PAX3-FOXO1 , which is involved in the particular muscle differentiation stage and in rhabdomyosarcoma. However, one intrachromosomal fusion, RP11-316I3.1-RP11-316I3.2 was seen in both MSC D26 and RH30, hinting that other fusions may also play a role in both processes.
DISCUSSION
Altogether, these results suggest that the PAX3-FOXO1 fusion product may commit MSCs to the myogenic lineage by transactivating expression of the essential myogenesis factors MYOD and MYOG . On the other hand, the transience of PAX3-FOXO1 RNA is consistent with the normal process of muscle differentiation, as prolonged production of PAX3-FOXO1 RNA leads to constant expression of MYOD and MYOG , which then blocks terminal differentiation ( 13, 14 ) . We reasoned that a posttranscriptional process, such as trans -splicing of precursor mRNAs, can give rise to transient, temporal appearance of the fusion product ( 16, 17 ) , whereas gene fusions caused by chromosomal translocation result in constitutive synthesis of chimeric PAX3-FOXO1 RNA, and in turn MYOD and MYOG expression that permanently arrests myocytes at immature forms, which can potentially lead to ARMS if combined with secondary mutations. Given the importance of the temporal and kinetic characteristics and patterns of the chimeric expression, we are now developing visualization systems to monitor the expression of the chimera along the muscle differentiation process.
The exact generating mechanism for the fusion is still not clear. The transient expression pattern and the absence of FOXO1 loci breakage suggest that the fusion is unlikely to be a product of chromosomal translocation. The RNA sequence at the junction is identical to the canonical splicing sites (exon 7 of PAX3 joined to exon 2 of FOXO1 ), consistent with an RNA trans -splicing mechanism. If proven true, PAX3-FOXO1 will be the second example of a chimeric RNA in normal cells 
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identical to a gene fusion product in cancer. The mechanism of such intergenic trans -splicing is not known. We speculate that it involves the expression and proximity of the parental transcripts. A longer intron tends to facilitate noncanonical splicing. In the case of PAX3-FOXO1 , FOXO1 intron 1 is the longest (over 100 kb). However, introns involved in JAZF1 are not the longest and intron 7 of PAX3 is also shorter than intron 4. It is also premature to specify other sequence features that are involved in homologous recombination, which may facilitate the fusion RNA generation, at this moment.
The PAX3-FOXO1 gene fusion is a prominent marker of ARMS and detection of PAX3-FOXO1 chimeric RNA by RT-PCR is a standard diagnostic procedure ( 18 ) . Therapies targeting the fusion protein have also been proposed ( 19 ) . Our fi ndings of the presence of PAX3-FOXO1 RNA in normal developing muscle samples raise concerns for false positive diagnoses, especially in the sensitive monitoring for residual disease. In addition, therapies targeted at the fusion protein may have side effects due to disruption of functions performed by chimeric PAX3-FOXO1 RNA in normal developing muscle. 
Rhabdomyosarcomas are generally considered skeletal muscle tumors, because of their morphologic muscle-like features. However, they can also arise at sites that normally lack skeletal muscle, such as the genitourinary and biliary tract. Despite extensive research, the exact cell of origin is still under debate (20) (21) (22) . Our data now suggest that the cell of origin for ARMS may be the cells that transiently express PAX3-FOXO1 . A connection between the production of chimeric PAX3-FOXO1 RNA during normal development and recombination between the two genes in cancer is more speculative. Nevertheless, such a connection is not unprecedented. At least in some lower organisms, such as various species of ciliates, RNA has been demonstrated to serve as a guide or template for DNA rearrangement ( 23, 24 ) .
METHODS

Cell Lines and Culture Conditions
Mesenchymal stem cells (MSC-7043L) were obtained from the Tulane University Center for Gene Therapy. Human embryonic stem cell-derived mesenchymal stem cells (hESC-MSC) were obtained from Millipore. These two cells were maintained in MEMα medium with 20% FBS. Adipose stem cells obtained from donors undergoing liposuction performed by Dr. Adam Katz were maintained in DMEM-F12 medium with 10% FBS. The rhabdomyosarcoma cell line RH30 was cultured in RPMI-1640 medium with 10% FBS. It was acquired from Dr. Anindya Dutta's laboratory (University of Virginia). No further authentication was done for the above cell lines. To induce muscle differentiation, cells were plated on 0.5% gelatin-coated plates and fed with Dulbecco's Modifi ed Eagle Medium (DMEM) containing 10% FBS, 0.1 μmol/L dexamethasone and 50 μmol/L hydrocortisone. Half of the medium was replaced every 4 days. Cells were harvested every other day ( 25 ) .
Clinical Samples
Nine FFPE sections from abortuses were collected. Skeletal muscle tissues were macrodissected, from which RNA was extracted. Fresh-frozen samples of abortuses were collected under approved Institutional Review Board protocol. When identifi able body parts were present, skeletal muscle from limbs was dissected. If not, whole specimens were used. RNA and protein were extracted using mortarpestle grinding in the presence of liquid N 2 .
NanoString nCounter
The NanoString nCounter system is a fl uorescence-based platform to detect individual mRNA molecules without reverse transcription and PCR amplifi cation ( 10 , 26 ) . In this system, each capture probe and reporter probe together query a contiguous region of approximately 100 bp and will hybridize to the target mRNA. RNA was extracted using TRIzol and further purifi ed with the RNeasy Kit (Qiagen). RNA lysates were hybridized to the probe set, incubated overnight at 65°C, washed, eluted according to the nCounter Prep Station manual, and counted by the nCounter Digital Analyzer. The raw data were normalized to the nCounter system spike-in positive and negative controls in each sample. The normalized results are further normalized against three reference genes: ACTB , HPRT , and RPLP0 .
FISH and Cytogenetic Analysis
Conventional cytogenetic analysis was performed using standard procedures as follows: cultures were initiated on 22-mm glass coverslips and incubated at 37°C in media consisting of MEM supplemented with FBS, penicillin/streptomycin, and L -glutamine. The cultures were examined daily and harvested as soon as adequate metaphase cells were present. The harvesting consisted of treatment with a 0.4% KCl hypotonic solution followed by fi xation with 3:1 methanol:acetic acid. The coverslips for the conventional analysis were treated with 0.01% trypsin followed by Giemsa staining. Cells were examined using an Olympus bright fi eld microscope. For both bone marrow and adipose-derived adult stem cells, 7 cells were analyzed and an additional 13 cells were scored for a total of 20 cells. Coverslips for FISH, harvested in the identical manner as described, were hybridized using standard procedures with the LSI FOXO1 (FOXO1, 13q14) break-apart probe set (Abbott). This probe set consists of a centromere-proximal green segment of 720 kb and a distal red segment of 650 kb. The normal, undisrupted signal is seen as a yellow signal or overlapping red and green signals. Disruptions of the region result in separate red and green signals. A total of 200 interphase nuclei were scored for disruption of the probe set for each cell line. A total of 100 nuclei were scored in a negative control and 50 in a positive control. For frozen sections of fetal muscle samples, at least 1,500 cells were scored on each slide.
Fusion RNA Detection
RNA-seq was performed by Axeq. Briefl y, the mRNA in total RNA was converted into a library of template molecules suitable for subsequent cluster generation using the reagents provided in the Illumina TruSeq RNA Sample Preparation Kit. Paired-end sequencing was then conducted using Hiseq 2000 (Illumina). The 101-bp RNA-seq data were then analyzed as described previously ( 27 ) . For the detection of fusion genes, we used defuse as described before ( 15 ) . The circular image results of alignments were presented using Circos ( 28 ) .
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